fibroscan

Co-hosts Louise Campbell and Roger Green are joined by friend of the podcast, Naim Alkhouri, and new guest, Professor James O’Beirne, to discuss learning from liver disease in Australia and developing improved models for patient identification and risk stratification.

This final conversation starts with Roger discussing the idea that upscaling training is very important. Louise follows up with a comment that we must remember these are complicated technologies to use and that dedication to training is pivotal in optimizing their potential. After a digression to consider the size of the indigenous candidates in the study, the group moves onto a final question. James shares what comes next in the study and the other panelists comment on what can be taken away from this discussion in terms of improving screening or cost effectiveness.

If you have questions or comments around the LOCATE-NAFLD study or any other ideas addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

Co-hosts Louise Campbell and Roger Green are joined by friend of the podcast, Naim Alkhouri, and new guest, Professor James O’Beirne, to discuss learning from liver disease in Australia and developing improved models for patient identification and risk stratification.

This conversation focuses largely on funding, starting with Louise’s question about Medicare payment for patients in Australia. James notes that all care was free to patients, and that this might skew results. As the conversation continues, Louise notes the importance for Australians of having Australian data to use in valuing medicines, diagnostics and procedures, given that NICE analyses rely exclusively on UK data. She goes on to ask about the quality of referrals from primary care, which prompts James to note that some primary care practitioners provided better data and novel referrals, while others appeared overwhelmed by the data. Roger asks the group how geographic dispersion will affect referrals as hepatologists push into primary care relationships. James suggests that geography is a challenge, leading Naim to comment that an inexpensive, hand-held device will be pivotal to mass screenings and that blood tests should be part of the mass screening armamentarium. James, followed by Louise, replies that nurses and some practitioners see imaging as a therapeutic event and an opportunity to engage the patient in a discussion of their numbers and how to improve lifestyles. As the conversation winds down, James and Naim discuss concerns around consistency of reads, and Louise, then Naim, provide tips on how to get a more accurate measurement.

If you have questions or comments around the LOCATE-NAFLD study or any other ideas addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

Co-hosts Louise Campbell and Roger Green are joined by friend of the podcast, Naim Alkhouri, and new guest, Professor James O’Beirne, to discuss learning from liver disease in Australia and developing improved models for patient identification and risk stratification.

This conversation starts with Louise discussing some of the improvements in patient motivation and compliance as a result of FibroScan when administered in specialty sites. From here Roger asks Louise and James how they envision practical implementation of this kind of study design in other countries. Louise speculates on how this might work in 3rd world countries where there are large distances between communities and concludes it is quite feasible when dieticians and other allied professionals are empowered and can conduct scans. Naim discusses the extensive free-scan program that Arizona Liver Health offers which is typically focused on patients with type 2 diabetes, obesity and other risk factors. James notes that one element of the design is that it can provide cost analysis to demonstrate cost effectiveness and generate public funding in single-payer countries. Naim identifies limitations in the design and ways these might be ameliorated over time. As the conversation closes, James suggests that one cost saving might come from reducing treatment for patients who do not have high risk of disease.

If you have questions or comments around the LOCATE-NAFLD study or any other ideas addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

Co-hosts Louise Campbell and Roger Green are joined by friend of the podcast, Naim Alkhouri, and new guest, Professor James O’Beirne, to discuss learning from liver disease in Australia and developing improved models for patient identification and risk stratification.

This conversation proceeds from a high-level overview of the LOCATE-NAFLD study. Discussion opens to comments from the panelists, starting with Naim commending the basic idea of a randomized study and the sample size for this initiative. He goes on to ruminate on how effective this design will be at correctly assessing positive and negative predictive values. James describes some of the funding and regulatory issues that shaped the design. As the conversation continues, it becomes clear that the median times to referral in the intervention and control groups were dramatically different and that these differences will have real clinical impact in a world with approved NASH agents. Louise raises the point that this kind of model can speed access to trial tremendously. James shares ideas around what motivated patients to enroll in the study and explains that significant numbers of patients screened out, most often due to high levels of alcohol consumption. As the conversation winds down, James mentions two interesting pieces of data from early analysis: a significant and clinically meaningful differences between successful FibroScan reads in the two groups and, separately, the lack of separation between the groups in quality of life scores.

If you have questions or comments around the LOCATE-NAFLD study or any other ideas addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

Co-hosts Louise Campbell and Roger Green are joined by friend of the podcast, Naim Alkhouri, and new guest, Professor James O’Beirne, to discuss liver disease in Australia and developing improved models for patient identification and risk stratification.

James , a Consultant Hepatologist at the Sunshine Coast University Hospital, shares his professional background and introduces events which lead to the LOCATE-NAFLD study. After Australia became the first country to allow access to direct-acting antiviral agents for HCV in 2016, there was the strong need to determine which patients were cirrhotic. With relatively unprepared primary care providers, specialist and hospital care were inundated with referrals. In response, James contributed to the inception of a mobile FibroScan program to deliver scans, assessments and treatment recommendations to community health clinics and GP practices. The program was very successful and it was decided that data should be published followed by an economic analysis to demonstrate how this was an effective model of democratizing access to risk stratification. As it was later sought to be applied to different disease areas, the LOCATE-NAFLD project was born. James outlines the parameters which can be read in a succinct overview here:

The LOCATE-NAFLD study is a 1:1 parallel randomized trial to compare two alternative models of care for NAFLD (usual care versus LOCATE-NAFLD).

Usual care group

• Patients will attend a specialist hepatology clinic for their care.

LOCATE-NAFLD group

• Patients will be assessed by a specialist study nurse in the primary care setting, such as local general practice clinic.
• The specialist nurse will assess patients using mobile transient elastography, using a FibroScan machine.
• Scan results will be reviewed by the specialist nurse and hepatologist
• Patients with low levels of liver scarring will be referred back to their GP for care
• Patients with high levels of liver scarring will be followed up in secondary care hepatology clinics

Quality of life will be assessed for all patients at baseline and at 12-month follow-up via a questionnaire. The study will analyse intervention costs, hospital outpatient clinic utilization, hospital admissions, hospital costs and patient death data.

From here the conversation opens to comments from the other panelists and Naim commends that this effort is being studied in a randomized trial and goes on to ask questions around protocol. Louise discusses the impact conducting FibroScan has on mediating patient behavior and the potential reach this sort of model has as she considers empowering the likes of dieticians and other skilled practitioners. Roger introduces ideas around extrapolating these insights for use in countries outside of Australia and goes on to discuss clinical care pathways and what motivating frontline treaters looks like both in the absence and presence of approved medications. Naim shares his experiences venturing into Arizona with mobile FibroScan consultations, mostly focused on patients with type 2 diabetes, obesity and other risk factors. The second half of the conversation touches more on economic analysis and the impact of improving technology on delivering more consistent results for scans. For final question, Roger prods James for what's next in this story and asks Louise and Naim what about this conversation influences their work and respective locations today.

If you have questions or comments around the LOCATE-NAFLD study or any other ideas addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On

In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:

• Approach to screening
• Barriers to screening (eg, test availability)
• Disease progression and complications
• Differentiating between coinfection and superinfection
• Approach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)
• Management of patients with decompensated cirrhosis
• Surrogate markers to measure treatment success
• Role of correcting thrombocytopenia before initiating therapy

Faculty:

Tarik Asselah, MD, PhD
Professor of Medicine 
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France

Ira Jacobson, MD
Professor of Medicine
NYU School of Medicine
Director of Hepatology
Division of Gastroenterology and Hepatology
NYU Langone Health
New York, New York

Link to full program: https://bit.ly/3yp1Lxf

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

This final conversation starts with Roger's closing question: if this group reconvenes in 18 months, how will the UK have progressed on this frontier? The answers vary but mostly center on issues of screening, issues of care and issues of data and analysis. 

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

In this session, each panelist offers their own take on where the devil is in the details can be applied to this subject. be themed. Much of the discussion comprises a fascinating interplay of ideas between Will and Louise about the best ways to implement community screening and more broadly, chronic disease management within the NHS system. Listen on to find out more.

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

Roger starts this conversation with a metaphor suggesting that as the FibroScan initiative takes shape, different stakeholders and communities might start out in different directions. Later, Louise suggests that the regions should rethink their funding to make it, as she puts it, bottom up instead of top down, and discusses other steps necessary to equalize delivery of quality scanning care throughout the US. Louise also mentions that the NHS recently announced investment in community scanning centers over the next two years in making all this work. The conversation winds down with Vanessa talking about work the British Liver Trust has done to assess different regions abilities to analyze and act on abnormal tests and more recently, conversations with integrated care boards on this topic. She goes on to discuss some of the challenges with producing change within NHS.

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than during the Surfing NASH  coverage of International #NASHDay 2023 . This conversation features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

This conversation starts with Roger providing a brief background on the Surfing NASH coverage of the NICE-FibroScan question. Vanessa is invited to share the work that her organization has done on this issue. She starts by describing the obligation that NICE has to take feedback from multiple stakeholders. She details a 16-month history of the discussion around this issue and the British Liver Trust's role in it. In the process, Vanessa elaborates on the value of anecdotes and patient-centered data in persuading NICE committees to think more expansively about the value of FibroScan and facilitating an alliance of professional societies in support of this campaign. Louise notes how revisions in data and models coupled with new perspectives led to a change in the NICE vision over time and produced this result. Will discusses the value of FibroScan and preventive hepatology, asserting that the level and nature of necessary data to prove the value of this intervention does not yet exist. He says that at the same time advocates promote use, these same stakeholders should "put our feet to the fire to produce evidence that will support the activity." Louise agrees and notes that the protocols will require those doing the scans to be trained and then assessed to assure quality. Finally, she agrees with Will that the stakeholders need to collect data from all locations to assure quality and that no such process exists today. Roger points out that previously on the podcast, Jeff Lazarus reported back in 2021 that the UK scored higher than any other country in its preparation for the NASH pandemic. Although it scored only 50 points on a 100-point scale, the joint NICE Guidance and NHS Funding initiative have the potential to boost that score significantly and start to build a demonstration model for other countries. Done right, it's an exciting, albeit challenging prospect.

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

This conversation continues focus on the concerns around appropriate data collection and analysis to discover the best path forward. Will describes the need to collect the kinds of data that will assess the value of the process and the right way to execute as processes are built and implemented. Vanessa agrees, but asks that we not let the perfect be the enemy of the good and that we keep in mind how many patients with advanced fibrosis are not getting diagnosed today and need the support of this program. One point that clearly emerges in dialogue with Will is that other countries will look to NICE and the UK experience to inform their own decisions. This only amplifies the need to collect data well and wisely. Louise states that she would also like to see data about the effect of this initiative on related metabolic conditions. She likens FibroScan scoring to dropping a pebble in a pond and seeks to explore the ripples it makes in related diseases and conditions, particularly for endocrinology and cardiology. Roger remarks on how refreshing it is to hear a conversation where multiple stakeholders are aligned to find the best approach to the disease. He goes on to contrast this topic to the role of ICER. Finally, Roger asks questions around Louise's pond metaphor and mentions comments that Stephen Harrison and Mazen Noureddin made last autumn that had suggested that FAST may be a better first line test. Will suggests that many questions need to be answered before determining the accuracy of the tests or what the best way to perform them is.

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH  ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

In addition, stay tuned for a session dedicated to International #NASHDay 2023 which will be released on Friday June 9th. If you have questions or interest around the event or FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

Surfing NASH returns to review the 2023 Innovations in NAFLD Care Workshop (INCBCN) which concluded on 27 May in Barcelona. Conference founders and directors Jeff Lazarus and Jörn Schattenberg discuss highlights and takeaways of the event with Louise Campbell and Roger Green.

This conversation starts with a focus on the opening session which is titled The Fatal Triple and End-Organ Injury. Embedded in the recap is the topic of alcohol consumption and how it contributes to Fatty Liver disease. The idea emerges that a standard unit of drink varies in definition and that there may be benefit to gathering structured consensus on the definition. The second part of this conversation considers facilitating FibroScan testing in different patient settings.

Listen on to discover the details revealed in the full episode. If you have questions or interest around the Innovations in NAFLD Care Workshop 2023, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

Surfing NASH returns to review the 2023 Innovations in NAFLD Care Workshop (INCBCN) which concluded on 27 May in Barcelona. Conference founders and directors Jeff Lazarus and Jörn Schattenberg discuss highlights and takeaways of the event with Louise Campbell and Roger Green.

This conversation captures the meeting in a broad sense by outlining its goals and reason for being. Jeff describes this year’s emphasis on expanding the community of practice beyond hepatology. For example, friend of the podcast and co-host of our Rising Tide series, Ken Cusi, chaired a session on the role of endocrinology and diabetology in the early diagnosis and management of NASH. In Jeff’s words, “We were trying to look at the liver more holistically and look at who else should be involved in a multidisciplinary approach.”

The discussion shifts to a review of the NASH-NITs Real-World-Evidence Summit. Jörn suggests that moving forward, the Summit ought to be expanded and broadened. After Jörn comments on the positive experience of facilitating hands-on engagement, Louise offers her take. She underscores that FibroScan testing requires adequate knowledge and training to be well-executed with precision. The group goes on to describe in detail what made the Summit unique and how it might grow in the future.

Listen on to discover the details revealed in the full episode. If you have questions or interest around the Innovations in NAFLD Care Workshop 2023, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!

This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable’ catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what’s to come in quarter two of 2023.

Roger opens this final conversation by noting his growing enthusiasm for International NASH Day 2023. This leads Jörn to share interesting anecdotes to describe how different cultures face different health threats. For example, in Germany he questions whether he should be revisiting his position on recommendations around alcohol consumption. As the session winds down, Roger alludes to exciting plans for a Surfing NASH 3rd anniversary special. The recording will take place on April 17th and we kindly invite those who are interested to participate as a live audience. For a final question, the Surfers visit what each thinks will be big ticket items for the second half of 2023 in the liver space. Louise looks to more education to bolster early detection. Jörn extends this thought to include the need for a clinical trial showing superiority of screening versus no screening in the general population. Lastly, Roger speaks to his contrasting interests around both the power of AI-assisted assessment of biopsy and the ability of consortia to demonstrate the effectiveness of NITs.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.


Stay Safe and Surf On!

This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable’ catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what’s to come in quarter two of 2023.

Roger begins this session by describing some of his anticipations around drug development in the second quarter, specifically pointing to emerging news on OCA and resmetirom. He also notes the possibility of new Phase 3 press releases on the horizon. Louise comments that with expected drug approvals, there needs to be more emphasis around allied health education, training and pathways. This leads Roger to share his belief that an approval in the US will lead to rather aggressive allied health education.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.
 

Stay Safe and Surf On!

This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable’ catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what’s to come in quarter two of 2023.

In this conversation, each Surfer picks one thing that's anticipated to happen in the second quarter that they think is likely to be most momentous or compelling. Louise leads with comments around the rigorous approval process of NICE for primary care access to FibroScan in the UK. While extensive, these protocols produce world-leading cost-benefit analysis. The group goes on to discuss how different systems contribute to progress in the field through different qualities. Louise asserts that facilitating frontline screening will enable early detection and ultimately help prevent cirrhosis for many patients. As the conversation winds down, Jörn offers notes on the upcoming EASL Congress and Roger shares his latest metaphor to describe the dynamism of fighting fatty liver disease. 

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.


Stay Safe and Surf On!

This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable’ catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what’s to come in quarter two of 2023. 

• Jörn recounts a productive trip to California where he attended the 3rd Annual Liver Connect Conference organized by the Chronic Liver Disease Foundation. He shares his highlights from the meeting, including a summary of a powerful presentation by Scott Friedman on ‘hot’ versus ‘cold’ fibrosis, cirrhosis, combination therapies and more. 
  
  
  
• Louise speaks to the intensity involved in reviewing publication for FibroScan approval in primary care pathways in the UK. One benefit of the lengthy protocols that NICE considers is that it ultimately produces world-leading cost-benefit analysis. The group goes on to discuss how different systems contribute to the field through their different strengths. 
  
  
  
• Roger uncovers a new metaphor for describing fatty liver disease and announces exciting plans for the podcast’s 3rd anniversary special.
   
  
  
• Among a number of other insights emerging from this session, the Surfers also discuss what is happening in the space of drug development and impending approvals, the strength in allied health professionals and primary care pathways for fighting fatty liver.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.


Stay Safe and Surf On!

The Surfers host a thought-provoking impromptu session on what’s happening thus far for the Fatty Liver field in 2023. Jörn Schattenberg leads this conversation with comments around diagnostic and therapeutic advancements following the momentum gathered at NASH-TAG in January. He points to the large number of abstracts (estimated at over 2500!) submitted to the upcoming EASL Congress held in Vienna this June. While drugs are leading the way, Jörn insists diagnostics are closely following and contributing to "excitement on both borders.” Roger Green notes activity around organizing trials that incorporate non-invasive endpoints.

Louise Campbell adds her highlight to be the recent AASLD guidance and its focus on clarifying CAP scores for improved FibroScan assessment. This is joint with eager anticipation of a NICE approval for access to FibroScan in the primary care setting. Roger comments on emerging competitor technologies, such as E-Scopics, and their influence on industry uptake of NITs. Combined with the various emerging guidelines and guidances, more doctors and specialties should begin focusing on how and when to test. Louise notes the potential challenges behind adopting liver-conscious practices for endocrinology and cardiology clinics in that there will be questions around how exactly this initiative is administered. However, these are exciting and surmountable challenges with rewarding implications. In Louise’s experience, “if you find real time with that person in the room, you can really make a change.” Roger connects these ideas around frontline screening to the podcast’s latest ventures in launching the Rising Tide series available at SurfingNASH.com. Lastly, he describes emerging energies around payer dynamics and drug utilization in the US.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On! 

In this episode, Coleman I. Smith, MD, and Lydia Tang, MBChB, discuss how to screen for hepatitis delta virus (HDV), including:

• Algorithm for evaluation of HDV
• Diagnosis of different stages of HDV infection 
• Strategies to increase HDV testing rates 

Faculty:
Coleman I. Smith, MD
Professor of Medicine
Hepatologist
Georgetown Transplant Institute
Georgetown University
Washington, DC

Lydia Tang, MBChB 
Assistant Professor
Department of Infectious Diseases
University of Maryland School of Medicine
Institute of Human Virology
Baltimore, Maryland

Link to full program:
http://bit.ly/41oYawr

Follow along with the slides at: 
http://bit.ly/3XW6m4g